• Facebook
  • Twitter
  • LinkedIn
  • Google +
  • RSS

UCB - Articles and news items

UCB and Amgen’s Osteoporosis study shows bone mineral density gains

Industry news / 18 November 2016 / Niamh Louise Marriott, Digital Content Producer

The BRIDGE study involved 245 men with osteoporosis randomised 2:1 to receive either 210 mg romosozumab or placebo subcutaneously once monthly for 1 year…

UCB and Amgen submit FDA application for Osteoporosis drug

Industry news / 22 July 2016 / Niamh Louise Marriott, Digital Content Producer

UCB and Amgen today announced the submission of a Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) for romosozumab, an investigational, monoclonal antibody for the treatment of osteoporosis in postmenopausal women at increased risk of fracture…

NICE recommends certolizumab pegol in draft guidance

Industry news / 12 July 2016 / Victoria White, Digital Content Producer

Certolizumab pegol is recommended as an option for people with severe rheumatoid arthritis when other drugs haven’t worked or aren’t suitable…

SMC accepts five new medicines for use in NHS Scotland

Industry news / 11 July 2016 / Victoria White, Digital Content Producer

The SMC has accepted five new medicines for routine use in NHS Scotland including lung cancer treatments nivolumab and crizotinib…

Bimekizumab demonstrates positive results in patients with psoriatic arthritis

Industry news / 10 June 2016 / Victoria White, Digital Content Producer

In a Phase Ib study, bimekizumab showed fast and sustained efficacy on disease activity measures in both skin and joints and was well-tolerated…

Positive top-line results from Phase III study of romosozumab in osteoporosis

Industry news / 21 March 2016 / Victoria White

The study demonstrated a statistically significant increase in bone mineral density at the lumbar spine in men with osteoporosis treated with romosozumab…

Brivaracetam launches in the UK as a new option for patients with uncontrolled epilepsy

Industry news / 29 February 2016 / Victoria White

UCB’s Briviact (brivaracetam) has been authorised in the UK as an add-on treatment for partial onset seizures with or without secondary generalised seizures…

Positive top-line results for romosozumab FRAME study

Industry news / 23 February 2016 / Victoria White

The Phase III FRAME study evaluated UCB and Amgen’s romosozumab in postmenopausal women with osteoporosis…

NICE recommends 7 DMARDs for severe rheumatoid arthritis

Industry news / 26 January 2016 / Victoria White

NICE recommends the seven biological disease modifying drugs as options for treating severe rheumatoid arthritis which has not responded to intensive therapy with a combination of conventional DMARDs…

Lannett completes acquisition of Kremers Urban Pharmaceuticals

Industry news / 27 November 2015 / Victoria White

Lannett has acquired KU from UCB for a total consideration of approximately US$1.23 billion…

UCB to sell Kremers Urban to Lannett

Industry news / 3 September 2015 / Victoria White

Lannett Company has entered into a definitive agreement to acquire UCB’s US generics subsidiary, Kremers Urban Pharmaceuticals, for $1.23 billion…

cimzia arthritis x-ray hands bones

Positive results from Phase 3 study evaluating Cimzia in DMARD-naïve rheumatoid arthritis patients

Industry news / 15 June 2015 / Victoria White

UCB has announced data from a Phase 3 study that showed the substantial benefits, at 52 weeks, of adding Cimzia to optimised methotrexate treatment…